Topic : TKIs

Other Topics :

Is a drug holiday ever possible?

A great deal of attention has been paid to “treatment-free remission” (TFR), where people who have been stable on treatment for many years are able to stop taking their TKI medication.
Continue Reading →

Stopping your CML meds

“Treatment-free remission” is the hottest topic in CML these days, with a number of studies exploring whether some people are able to stop taking their medication.
Continue Reading →

Generic Gleevec – Is the same the same?

American Society of Hematology 57th Annual Meeting, Orlando FL, December 5-8, 2015 – Brand-name drugs are new therapies (or “me-too” drugs) that are rigorously tested before they are allowed on the market by regulatory bodies, such as the U.S. Food and Drug Administration or Hea
Continue Reading →

Treatment-free remission – how well do people do?

A new goal in treating CML is treatment-free remission (TFR). What this means is that CML is so deeply suppressed with treatment that the person is able to stop the medication altogether and the leukemia doesn’t return. The physical advantages of TFR will be obvious to anyone taking o
Continue Reading →

Treating CML early – a cautionary tale

It’s not always a simple matter to get access to the medications you need, but a delay in starting treatment for CML can jeopardize the success of therapy. This was shown in a recent study conducted in Bosnia, where people often face considerable red tape before they can start a
Continue Reading →

Current CML treatment studies in Canada

Chronic myelogenous leukemia is a hot area of medical research, in part because of the development of the first effective treatment (Gleevec) a decade ago and the insights about the biology of the disease that have resulted from that important discovery.
Continue Reading →

Surviving CML

CML was once considered a death sentence, with people typically living only a few years after being diagnosed. But have TKI medications, such as Gleevec, Sprycel, Tasigna or Bosulif, actually made a difference?
Continue Reading →

Comparing CML treatments

Many people with CML start treatment with a second-generation medication, such as Sprycel or Tasigna, because they more potently suppress the proliferation of leukemia cells. But how do these two medications compare?
Continue Reading →

Treating your CML: results at 6 years

Many people with CML start treatment with a second-generation agent (e.g. Tasigna or Sprycel) instead of Gleevec because they’re more likely to achieve a faster, deeper response.
Continue Reading →

ASCO 2015: Updated results for Bosulif in CML

Report from the American Society of Clinical Oncology (ASCO), Chicago IL, May 29-June 2, 2015 – Bosulif (bosutinib) is one of the more recent TKIs used for the treatment of CML. It’s a potent drug that is generally kept in reserve for people with an inadequate response or poor t
Continue Reading →